Raymond James Financial’s PDS Biotechnology PDSB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-33,819
Closed -$29.8K – 5602
2026
Q2
$29.8K Buy
33,819
+23,583
+230% +$25K ﹤0.01% 5307
2026
Q1
$6.19K Sell
10,236
-3,500
-25% -$2.63K ﹤0.01% 5268
2025
Q4
$10.6K Sell
13,736
-40
-0.3% -$36 ﹤0.01% 5136
2025
Q3
$13.9K Sell
13,776
-89
-0.6% -$105 ﹤0.01% 4922
2025
Q2
$18.4K Sell
13,865
-100
-0.7% -$136 ﹤0.01% 5633
2025
Q1
$16.6K Sell
13,965
-1,900
-12% -$2.7K ﹤0.01% 4733
2024
Q4
$25.9K Buy
+15,865
New +$42K ﹤0.01% 4693

Other funds holding PDSB

Raymond James Financial's PDSB Position: Q3 2026 in Review

Raymond James Financial sold out of PDS Biotechnology (PDSB) in Q3 2026, closing a stake of 33,819 shares — an estimated $29.8K sold.

Raymond James Financial first reported a position in PDSB in Q4 2024 and held it in 7 quarters. The position peaked at $29.8K in Q2 2026. 60 funds tracked by Wall St. Rank hold PDSB as of Q3 2026.

  • Raymond James Financial reported no remaining PDS Biotechnology position as of Q3 2026 after selling out during the quarter.
  • Raymond James Financial sold 33,819 PDS Biotechnology shares in Q3 2026, an estimated $29.8K.
  • Raymond James Financial first reported a position in PDS Biotechnology in Q4 2024 and held it in 7 quarters.
  • Raymond James Financial's PDS Biotechnology position peaked at $29.8K in Q2 2026.
  • 60 funds tracked by Wall St. Rank held PDS Biotechnology as of Q3 2026.

Based on Raymond James Financial's 13F filing for Q3 2026, filed 12 Nov 2026.